S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
NASDAQ:XOMA

XOMA (XOMA) Stock Price, News & Analysis

$24.05
+0.71 (+3.04%)
(As of 03/28/2024 ET)
Today's Range
$23.25
$24.32
50-Day Range
$19.52
$26.32
52-Week Range
$13.48
$26.83
Volume
19,834 shs
Average Volume
20,361 shs
Market Capitalization
$279.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$74.00

XOMA MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
207.7% Upside
$74.00 Price Target
Short Interest
Healthy
2.36% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.22
Upright™ Environmental Score
News Sentiment
0.97mentions of XOMA in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.73) to ($1.36) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.07 out of 5 stars

Medical Sector

208th out of 938 stocks

Pharmaceutical Preparations Industry

91st out of 433 stocks

XOMA stock logo

About XOMA Stock (NASDAQ:XOMA)

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.

XOMA Stock Price History

XOMA Stock News Headlines

XOMA Declares Quarterly Preferred Stock Dividends
Claim Your Complimentary Bitcoin Reward
Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.
Grab Your Free Bitcoin Today!
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
XOMA to Present at Upcoming Investor Conferences in March
XOMA Mar 2024 20.000 put
XOMA Jun 2024 25.000 call
XOMA Agrees to Acquire Kinnate Biopharma
See More Headlines
Receive XOMA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for XOMA and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/08/2024
Today
3/29/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:XOMA
CUSIP
98419J10
Employees
13
Year Founded
1981

Price Target and Rating

Average Stock Price Target
$74.00
High Stock Price Target
$74.00
Low Stock Price Target
$74.00
Potential Upside/Downside
+207.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-40,830,000.00
Net Margins
-886.91%
Pretax Margin
-858.16%

Debt

Sales & Book Value

Annual Sales
$4.76 million
Book Value
$7.72 per share

Miscellaneous

Free Float
11,021,000
Market Cap
$279.70 million
Optionable
Optionable
Beta
0.58

Social Links

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

XOMA Stock Analysis - Frequently Asked Questions

Should I buy or sell XOMA stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for XOMA in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" XOMA shares.
View XOMA analyst ratings
or view top-rated stocks.

What is XOMA's stock price target for 2024?

1 Wall Street analysts have issued twelve-month price targets for XOMA's shares. Their XOMA share price targets range from $74.00 to $74.00. On average, they predict the company's share price to reach $74.00 in the next year. This suggests a possible upside of 207.7% from the stock's current price.
View analysts price targets for XOMA
or view top-rated stocks among Wall Street analysts.

How have XOMA shares performed in 2024?

XOMA's stock was trading at $18.50 on January 1st, 2024. Since then, XOMA stock has increased by 30.0% and is now trading at $24.05.
View the best growth stocks for 2024 here
.

When is XOMA's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our XOMA earnings forecast
.

How were XOMA's earnings last quarter?

XOMA Co. (NASDAQ:XOMA) announced its quarterly earnings data on Friday, March, 8th. The biotechnology company reported ($0.49) earnings per share for the quarter, missing analysts' consensus estimates of ($0.36) by $0.13. The biotechnology company earned $1.83 million during the quarter, compared to analyst estimates of $1.01 million. XOMA had a negative trailing twelve-month return on equity of 25.17% and a negative net margin of 886.91%.

What is John Varian's approval rating as XOMA's CEO?

11 employees have rated XOMA Chief Executive Officer John Varian on Glassdoor.com. John Varian has an approval rating of 73% among the company's employees.

What other stocks do shareholders of XOMA own?

Based on aggregate information from My MarketBeat watchlists, some companies that other XOMA investors own include Cytokinetics (CYTK), Alnylam Pharmaceuticals (ALNY), Ascent Solar Technologies (ASTI), CTI BioPharma (CTIC), OPKO Health (OPK), Uranium Energy (UEC), Gilead Sciences (GILD), NXP Semiconductors (NXPI) and Ekso Bionics (EKSO).

Who are XOMA's major shareholders?

XOMA's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (3.67%), Vanguard Group Inc. (3.67%), Opaleye Management Inc. (2.18%), Stonepine Capital Management LLC (2.18%), Dimensional Fund Advisors LP (0.22%) and Barclays PLC (0.09%). Insiders that own company stock include Bradley Sitko, Bvf Partners L P/Il, James R Neal, James R Neal, Owen Hughes and Thomas M Burns.
View institutional ownership trends
.

How do I buy shares of XOMA?

Shares of XOMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:XOMA) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners